Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Sangamo Therapeutics (SGMO) over the last 16 years, with Q3 2025 value amounting to $151000.0.

  • Sangamo Therapeutics' Change in Receivables fell 9847.71% to $151000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.0 million, marking a year-over-year decrease of 20668.59%. This contributed to the annual value of -$397000.0 for FY2024, which is 8558.98% up from last year.
  • Latest data reveals that Sangamo Therapeutics reported Change in Receivables of $151000.0 as of Q3 2025, which was down 9847.71% from $6000.0 recorded in Q2 2025.
  • In the past 5 years, Sangamo Therapeutics' Change in Receivables registered a high of $9.9 million during Q3 2024, and its lowest value of -$10.0 million during Q4 2024.
  • For the 5-year period, Sangamo Therapeutics' Change in Receivables averaged around -$247421.1, with its median value being -$160000.0 (2025).
  • Within the past 5 years, the most significant YoY rise in Sangamo Therapeutics' Change in Receivables was 73233.42% (2024), while the steepest drop was 433111.11% (2024).
  • Sangamo Therapeutics' Change in Receivables (Quarter) stood at -$2.0 million in 2021, then soared by 56.81% to -$844000.0 in 2022, then soared by 73.34% to -$225000.0 in 2023, then tumbled by 4331.11% to -$10.0 million in 2024, then skyrocketed by 101.51% to $151000.0 in 2025.
  • Its Change in Receivables was $151000.0 in Q3 2025, compared to $6000.0 in Q2 2025 and -$160000.0 in Q1 2025.